array(3) {
["company_details"]=>
array(13) {
["name"]=>
string(29) "Regeneron Pharmaceuticals Inc"
["slug"]=>
string(38) "c469a-us-regeneron-pharmaceuticals-inc"
["logo"]=>
string(84) "https://images.businessradar.com/linkedin_logos/b5187988-884a-43b7-980d-e1555548ab77"
["description"]=>
string(868) "At Regeneron we believe that when the right idea finds the right team, powerful change is possible. As we work across our expanding global network to invent, develop and commercialize life-transforming medicines for people with serious diseases, we’re establishing new ways to think about science, manufacturing and commercialization. And new ways to think about health. Connect with us so we can learn more about you, and you can learn more about our biopharmaceutical medicines. And join us, as we build a future we believe in.
Please visit www.regeneron.com/social-media-terms for information on how to engage with us on social media.
An important note about privacy: Regeneron is committed to your privacy and will not ask for sensitive personal information such as social security number, date of birth or bank account details via email or social media. "
["address_street"]=>
string(25) "777 Old Saw Mill River Rd"
["address_place"]=>
string(9) "Tarrytown"
["address_region"]=>
string(8) "New York"
["founding_date"]=>
string(10) "1988-02-08"
["website_domain"]=>
string(13) "regeneron.com"
["website_url"]=>
string(25) "https://www.regeneron.com"
["industry_codes"]=>
array(1) {
[0]=>
string(27) "Pharmaceutical Preparations"
}
["employee_count"]=>
int(10368)
["article_count"]=>
int(2445)
}
["articles"]=>
array(9) {
[0]=>
array(7) {
["title_en"]=>
string(103) "Regeneron Pharmaceuticals Stock Upgraded After Q3, But There Is A Headwind - Analyst Review By Benzinga"
["snippet_en"]=>
string(91) "Regeneron Pharmaceuticals Stock Upgraded After Q3, But There Is A Headwind - Analyst Review"
["url"]=>
string(145) "https://uk.investing.com/news/stock-market-news/regeneron-pharmaceuticals-stock-upgraded-after-q3-but-there-is-a-headwind--analyst-review-3222136"
["image_url"]=>
NULL
["source"]=>
string(13) "investing.com"
["publication_date"]=>
string(10) "2023-11-03"
["categories"]=>
array(4) {
[0]=>
string(24) "Quarterly/Annual Figures"
[1]=>
string(24) "Stock Research & Ratings"
[2]=>
string(14) "Product Review"
[3]=>
string(12) "Stock Market"
}
}
[1]=>
array(7) {
["title_en"]=>
string(95) "Contemporary Pediatrics week in review: FDA approvals, gut microbiomes, and back-to-school tips"
["snippet_en"]=>
string(137) "Review some of the top stories from the Contemporary Pediatrics website over the last week, and catch up on anything you may have missed."
["url"]=>
string(136) "https://www.contemporarypediatrics.com/view/contemporary-pediatrics-week-in-review-fda-approvals-gut-microbiomes-and-back-to-school-tips"
["image_url"]=>
string(78) "https://images.businessradar.com/articles/29fa1798-0ced-4b46-a369-8f598486e423"
["source"]=>
string(26) "contemporarypediatrics.com"
["publication_date"]=>
string(10) "2023-08-21"
["categories"]=>
array(1) {
[0]=>
string(14) "Product Review"
}
}
[2]=>
array(7) {
["title_en"]=>
string(61) "Regeneron's (REGN) Application for Blood Cancer Drug Accepted"
["snippet_en"]=>
string(187) "Regeneron Pharmaceuticals, Inc. REGN announced that the European Medicines Agency accepted to review the Marketing Authorization Application (MAA) for its pipeline candidate odronextamab."
["url"]=>
string(90) "https://www.nasdaq.com/articles/regenerons-regn-application-for-blood-cancer-drug-accepted"
["image_url"]=>
NULL
["source"]=>
string(10) "nasdaq.com"
["publication_date"]=>
string(10) "2023-08-18"
["categories"]=>
array(1) {
[0]=>
string(14) "Product Review"
}
}
[3]=>
array(7) {
["title_en"]=>
string(51) "EU to review Regeneron's lymphoma drug odronextamab"
["snippet_en"]=>
string(231) "Tarrytown-headquartered Regeneron Pharmaceuticals Inc. (NASDAQ: REGN) announced that the European Medicines Agency (EMA) has accepted for review the Marketing Authorization Application (MAA) for its lymphoma treatment odronextamab."
["url"]=>
string(87) "https://westfaironline.com/medicine/eu-to-review-regenerons-lymphoma-drug-odronextamab/"
["image_url"]=>
string(78) "https://images.businessradar.com/articles/05fbd1c4-1efe-48fe-bcb7-ea9c1b1a89b4"
["source"]=>
string(18) "westfaironline.com"
["publication_date"]=>
string(10) "2023-08-18"
["categories"]=>
array(2) {
[0]=>
string(14) "Product Review"
[1]=>
string(22) "EU Political Evolution"
}
}
[4]=>
array(7) {
["title_en"]=>
string(52) "Regeneron Pharma: EMA To Review MAA For Odronextamab"
["snippet_en"]=>
string(280) "(RTTNews) - Regeneron Pharmaceuticals, Inc. (REGN) announced the European Medicines Agency has accepted for review the Marketing Authorization Application for odronextamab to treat adult patients with relapsed/refractory follicular lymphoma or R/R diffuse large B-cell lymphoma, w"
["url"]=>
string(84) "https://www.nasdaq.com/articles/regeneron-pharma:-ema-to-review-maa-for-odronextamab"
["image_url"]=>
NULL
["source"]=>
string(10) "nasdaq.com"
["publication_date"]=>
string(10) "2023-08-17"
["categories"]=>
array(1) {
[0]=>
string(14) "Product Review"
}
}
[5]=>
array(7) {
["title_en"]=>
string(66) "FDA to review dupilumab for treating chronic spontaneous urticaria"
["snippet_en"]=>
string(87) "Dupilumab enters the approval process for adolescents and adults with uncontrolled CSU."
["url"]=>
string(119) "https://www.mdedge.com/dermatology/article/261657/medical-dermatology/fda-review-dupilumab-treating-chronic-spontaneous"
["image_url"]=>
NULL
["source"]=>
string(10) "mdedge.com"
["publication_date"]=>
string(10) "2023-03-08"
["categories"]=>
array(1) {
[0]=>
string(14) "Product Review"
}
}
[6]=>
array(7) {
["title_en"]=>
string(61) "Regeneron (REGN) Rare Disease Drug Gets FDA's Priority Review"
["snippet_en"]=>
string(232) "Regeneron Pharmaceuticals, Inc. REGN announced that the FDA has accepted for Priority Review the biologics license application (BLA) for pozelimab. The regulatory body has set a target action date of Aug 20, 2023, for the candidate."
["url"]=>
string(90) "https://www.nasdaq.com/articles/regeneron-regn-rare-disease-drug-gets-fdas-priority-review"
["image_url"]=>
NULL
["source"]=>
string(10) "nasdaq.com"
["publication_date"]=>
string(10) "2023-02-21"
["categories"]=>
array(1) {
[0]=>
string(14) "Product Review"
}
}
[7]=>
array(7) {
["title_en"]=>
string(67) "Regeneron Pharma: FDA Accepts For Priority Review BLA For Pozelimab"
["snippet_en"]=>
string(279) "(RTTNews) - Regeneron Pharmaceuticals, Inc. (REGN) announced the FDA has accepted for Priority Review the Biologics License Application for pozelimab as a treatment for adults and children as young as 1 year of age with CHAPLE disease. The target action date for the FDA decision"
["url"]=>
string(99) "https://www.nasdaq.com/articles/regeneron-pharma:-fda-accepts-for-priority-review-bla-for-pozelimab"
["image_url"]=>
NULL
["source"]=>
string(10) "nasdaq.com"
["publication_date"]=>
string(10) "2023-02-21"
["categories"]=>
array(1) {
[0]=>
string(14) "Product Review"
}
}
[8]=>
array(7) {
["title_en"]=>
string(57) "Regeneron Gets FDA Priority Review of Pozelimab in Chaple"
["snippet_en"]=>
string(266) "By Colin Kellaher Regeneron Pharmaceuticals Inc. on Tuesday said the U.S. Food and Drug Administration granted priority review to its application seeking approval of pozelimab for the treatment of an ultra-rare and life-threatening hereditary immune d... | Feb. 21"
["url"]=>
string(151) "https://www.marketscreener.com/amp/quote/stock/REGENERON-PHARMACEUTICALS-10649/news/Regeneron-Gets-FDA-Priority-Review-of-Pozelimab-in-Chaple-43041947/"
["image_url"]=>
string(78) "https://images.businessradar.com/articles/b16b0902-32b8-4049-88b9-170126c08fa2"
["source"]=>
string(18) "marketscreener.com"
["publication_date"]=>
string(10) "2023-02-21"
["categories"]=>
array(1) {
[0]=>
string(14) "Product Review"
}
}
}
["category_annotations"]=>
array(30) {
[0]=>
array(2) {
["name"]=>
string(12) "Stock Market"
["count"]=>
int(197)
}
[1]=>
array(2) {
["name"]=>
string(8) "Epidemic"
["count"]=>
int(193)
}
[2]=>
array(2) {
["name"]=>
string(5) "Legal"
["count"]=>
int(152)
}
[3]=>
array(2) {
["name"]=>
string(24) "Quarterly/Annual Figures"
["count"]=>
int(101)
}
[4]=>
array(2) {
["name"]=>
string(5) "Award"
["count"]=>
int(95)
}
[5]=>
array(2) {
["name"]=>
string(17) "Academic Research"
["count"]=>
int(83)
}
[6]=>
array(2) {
["name"]=>
string(5) "Event"
["count"]=>
int(70)
}
[7]=>
array(2) {
["name"]=>
string(13) "Collaboration"
["count"]=>
int(61)
}
[8]=>
array(2) {
["name"]=>
string(18) "Expansion & Growth"
["count"]=>
int(51)
}
[9]=>
array(2) {
["name"]=>
string(10) "Litigation"
["count"]=>
int(50)
}
[10]=>
array(2) {
["name"]=>
string(11) "Acquisition"
["count"]=>
int(46)
}
[11]=>
array(2) {
["name"]=>
string(18) "General Investment"
["count"]=>
int(44)
}
[12]=>
array(2) {
["name"]=>
string(5) "R & D"
["count"]=>
int(35)
}
[13]=>
array(2) {
["name"]=>
string(24) "Stock Research & Ratings"
["count"]=>
int(35)
}
[14]=>
array(2) {
["name"]=>
string(14) "Issuing Shares"
["count"]=>
int(34)
}
[15]=>
array(2) {
["name"]=>
string(46) "Management of Legal and Regulatory Environment"
["count"]=>
int(33)
}
[16]=>
array(2) {
["name"]=>
string(12) "Board Change"
["count"]=>
int(33)
}
[17]=>
array(2) {
["name"]=>
string(15) "Deals & Tenders"
["count"]=>
int(32)
}
[18]=>
array(2) {
["name"]=>
string(21) "Competitive Behaviour"
["count"]=>
int(31)
}
[19]=>
array(2) {
["name"]=>
string(15) "Market Movement"
["count"]=>
int(31)
}
[20]=>
array(2) {
["name"]=>
string(14) "Product Review"
["count"]=>
int(31)
}
[21]=>
array(2) {
["name"]=>
string(31) "Financial Update/Profit Warning"
["count"]=>
int(30)
}
[22]=>
array(2) {
["name"]=>
string(27) "Business Model & Innovation"
["count"]=>
int(29)
}
[23]=>
array(2) {
["name"]=>
string(8) "Verdicts"
["count"]=>
int(29)
}
[24]=>
array(2) {
["name"]=>
string(14) "Product Launch"
["count"]=>
int(27)
}
[25]=>
array(2) {
["name"]=>
string(11) "Competition"
["count"]=>
int(26)
}
[26]=>
array(2) {
["name"]=>
string(13) "Data Security"
["count"]=>
int(24)
}
[27]=>
array(2) {
["name"]=>
string(24) "Access and affordability"
["count"]=>
int(23)
}
[28]=>
array(2) {
["name"]=>
string(11) "Sponsorship"
["count"]=>
int(20)
}
[29]=>
array(2) {
["name"]=>
string(8) "Politics"
["count"]=>
int(20)
}
}
}
c469a-us-regeneron-pharmaceuticals-inc
Regeneron Pharmaceuticals Inc
Location
New York
Founded
1988-02-08
Website
https://www.regeneron.com
Articles
2445 Articles
Category
Pharmaceutical Preparations
Description
At Regeneron we believe that when the right idea finds the right team, powerful change is possible. As we work across our expanding global network to invent, develop and commercialize life-transforming medicines for people with serious diseases, we’re establishing new ways to think about science, manufacturing and commercialization. And new ways to think about health. Connect with us so we can learn more about you, and you can learn more about our biopharmaceutical medicines. And join us, as we build a future we believe in.
Please visit www.regeneron.com/social-media-terms for information on how to engage with us on social media.
An important note about privacy: Regeneron is committed to your privacy and will not ask for sensitive personal information such as social security number, date of birth or bank account details via email or social media.
Regeneron Pharmaceuticals, Inc. REGN announced that the European Medicines Agency accepted to review the Marketing Authorization Application (MAA) for its pipeline candidate odronextamab.
Tarrytown-headquartered Regeneron Pharmaceuticals Inc. (NASDAQ: REGN) announced that the European Medicines Agency (EMA) has accepted for review the Marketing Authorization Application (MAA) for its lymphoma treatment odronextamab.
(RTTNews) - Regeneron Pharmaceuticals, Inc. (REGN) announced the European Medicines Agency has accepted for review the Marketing Authorization Application for odronextamab to treat adult patients with relapsed/refractory follicular lymphoma or R/R diffuse large B-cell lymphoma, w
Regeneron Pharmaceuticals, Inc. REGN announced that the FDA has accepted for Priority Review the biologics license application (BLA) for pozelimab. The regulatory body has set a target action date of Aug 20, 2023, for the candidate.
(RTTNews) - Regeneron Pharmaceuticals, Inc. (REGN) announced the FDA has accepted for Priority Review the Biologics License Application for pozelimab as a treatment for adults and children as young as 1 year of age with CHAPLE disease. The target action date for the FDA decision
By Colin Kellaher Regeneron Pharmaceuticals Inc. on Tuesday said the U.S. Food and Drug Administration granted priority review to its application seeking approval of pozelimab for the treatment of an ultra-rare and life-threatening hereditary immune d... | Feb. 21
To provide the best experiences, we use technologies like cookies to store and/or access device information. Consenting to these technologies will allow us to process data such as browsing behavior or unique IDs on this site. Not consenting or withdrawing consent, may adversely affect certain features and functions.
Functional
Always active
The technical storage or access is strictly necessary for the legitimate purpose of enabling the use of a specific service explicitly requested by the subscriber or user, or for the sole purpose of carrying out the transmission of a communication over an electronic communications network.
Preferences
The technical storage or access is necessary for the legitimate purpose of storing preferences that are not requested by the subscriber or user.
Statistics
The technical storage or access that is used exclusively for statistical purposes.The technical storage or access that is used exclusively for anonymous statistical purposes. Without a subpoena, voluntary compliance on the part of your Internet Service Provider, or additional records from a third party, information stored or retrieved for this purpose alone cannot usually be used to identify you.
Marketing
The technical storage or access is required to create user profiles to send advertising, or to track the user on a website or across several websites for similar marketing purposes.
